See our Locations
We offer career development opportunities in over 170 locations across the world. Explore some of our featured locations.
Search
Boehringer Ingelheim - Life Forward
Boehringer Ingelheim is one of the world’s leading familyowned pharmaceutical companies,developing medicines to address unmet needs in human and animal
Scleroderma
Scleroderma
Our culture
Our culture reflects who we are and is reflected in Our FOCUS and strong belief in Diversity, Equity and Inclusion as well as Sustainable Development.
Lung Diseases
Our Therapeutic Areas
More Potential
More Potential
Benefits & Rewards
We invest in our people so they will stay and grow with us. We offer benefits such as rewards and development opportunities to help retain employees.
Heart Failure
Heart Failure
A Planned Safety Net for Patients in Need
A Planned Safety Net for Patients in Need
Celebrating Innovation | Partnering
BI’s Innovation Prize was established in Boston in 2015 to recognize the challenge and dedication of entrepreneurs in advancing new ideas & science.
Purchasing
Suppliers are an integral part of our success. We are passionate about solutions and new opportunities to review, improve and optimize our supplier base.
Heart Diseases
Heart Diseases
Contact Us
Contact Us
Immunology
Immunology
Boehringer Ingelheim Enhances Oncology R&D with Novel MacroDel Delivery Technology Via Acquisition of ICD Therapeutics
Boehringer Ingelheim Enhances Oncology R&D with Novel MacroDel Delivery Technology Via Acquisition of ICD Therapeutics
New consortium EUbOPEN will provide tools to unlock disease biolog
New consortium EUbOPEN will provide tools to unlock disease biolog
Oncology & Cancer Immunology
Oncology & Cancer Immunology
Boehringer Ingelheim Partners with Thoeris to Investigate a Novel Approach to Treat Urea Cycle Disorders
Boehringer Ingelheim Partners with Thoeris to Investigate a Novel Approach to Treat Urea Cycle Disorders
Boehringer Ingelheim US Veterinary Scholars Program Profiles | Boehringer Ingelheim US
Click here to find out more how the Boehringer Ingelheim veterinary scholars program has helped 3,500 people over 30 years. Read five of their stories here.
Boehringer Ingelheim Acquires AMAL Therapeutics
Boehringer Ingelheim Acquires AMAL Therapeutics
Boehringer Ingelheim Advances First Pan-KRAS Inhibitor BI 1701963 into Clinical Testing
Boehringer Ingelheim Advances First Pan-KRAS Inhibitor BI 1701963 into Clinical Testing
Medical Affairs & Scientific Comms. | Boehringer Ingelheim US
Boehringer Ingelheim is proud to offer a 2-year, rotation-based, Fellowship program within Medical Affairs & Scientific Communications.
From garage start-up to global pharma: combining strengths to advance regenerative medicine
Article describing how a strategic partnership between Global Stem Cell and Boehringer Ingelheim Animal Health has played a key role in helping the companies accelerate breakthroughs in regenerative medicine.
Ridgefield, CT | BI Facilities
BI was established in Connecticut in 1971 and broke ground on September 1st, 1989 in Ridgefield. This site is home to the U.S. HQ of Boehringer Ingelheim
Sunshine Act Compliance
Sunshine Act Compliance